Compare ClearPoint Neuro Inc (CLPT) vs Charles Schwab Corporation Common Stock (SCHW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ClearPoint Neuro Inc vs Charles Schwab Corporation Common Stock — how do they compare? ClearPoint Neuro Inc trades at $15.7 (market cap $478.63M), while Charles Schwab Corporation Common Stock trades at $101.41 (market cap $175.83B). The key difference: Charles Schwab Corporation Common Stock is far larger — about 367.4× ClearPoint Neuro Inc's market cap, and Charles Schwab Corporation Common Stock pays a 1.27% dividend while ClearPoint Neuro Inc pays none. Which is the better fit depends on your goals.
| CLPT | SCHW | |
|---|---|---|
Market Cap | $478.63M | $175.83B |
Sector | Health | Financials |
52-Week High | $29.60 | $107.21 |
52-Week Low | $8.66 | $85.35 |
Enterprise Value | $506.63M | — |
Dividend Yield | — | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ClearPoint Neuro (CLPT) trades at $16.51, down 5.66% on the day, with a bullish technical signal from moving averages but negative profitability. The company reported record Q1 2026 revenue of $36.97M with 25% organic device growth, though it missed EPS estimates with a $0.32 loss. Recent FDA clearance for the Velocity Alpha surgical drill and a partnership with Sungkyunkwan University highlight expansion efforts in neurosurgical navigation and drug delivery.
Outlook remains speculative with 100% analyst buy ratings anticipating gene therapy commercialization upside, but high execution and regulatory risks persist amid consistent losses and negative margins. The stock's valuation at 11.31x sales reflects growth expectations, yet cash burn from operations requires careful monitoring of financing sustainability.
Charles Schwab (SCHW) trades at $102.38, down 0.72% on the day, with a bullish technical outlook and strong fundamentals. Recent earnings beats, including Q1 2026 EPS of $1.43 versus $1.40 expected, highlight robust profitability. The stock is supported by a 21.79% ROE and a net income margin of 37.99%, with revenue growth to $23.92 billion in 2025. Positive sentiment is fueled by a Zacks Strong Buy upgrade and a consensus price target of $122.71, suggesting 20% upside.
Outlook remains favorable given earnings momentum and retail trading growth, but risks include interest rate sensitivity and competitive pressures. Analyst consensus is 58% buy, with institutional confidence bolstered by a recent dividend payment. The stock's valuation at a P/E of 20.35 appears reasonable relative to growth, though high RSI levels indicate potential near-term consolidation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ClearPoint Neuro Inc
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →About Charles Schwab Corporation Common Stock
Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.
Read more on SCHW →
